Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
160
Enrollment
INDUSTRY
Sponsor class
Conditions
Plaque Psoriasis
Interventions
DRUG:
ORKA-002
OTHER:
Placebo
Sponsor
Oruka Therapeutics, Inc.